



A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

NAME : Mr. VIRENDER

AGE/ GENDER : 29 YRS/MALE **PATIENT ID** : 1792547

COLLECTED BY REG. NO./LAB NO. : 122503150024

REFERRED BY **REGISTRATION DATE** : 15/Mar/2025 04:51 PM BARCODE NO. : 12507523 **COLLECTION DATE** : 15/Mar/2025 04:58PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 15/Mar/2025 09:49PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval Test Name**

HAEMATOLOGY HAEMOGLOBIN (HB)

13.9 HAEMOGLOBIN (HB) 12.0 - 17.0 gm/dL

by CALORIMETRIC

INTERPRETATION:-Hemoglobin is the protein molecule in red blood cells that carries oxygen from the lungs to the bodys tissues and returns carbon dioxide from the tissues back to the lungs.

A low hemoglobin level is referred to as ANEMIA or low red blood count.

ANEMIA (DECRESED HAEMOGLOBIN):

1) Loss of blood (traumatic injury, surgery, bleeding, colon cancer or stomach ulcer)

2) Nutritional deficiency (iron, vitamin B12, folate)

- 3) Bone marrow problems (replacement of bone marrow by cancer)
- 4) Suppression by red blood cell synthesis by chemotherapy drugs

5) Kidney failure

6) Abnormal hemoglobin structure (sickle cell anemia or thalassemia).

POLYCYTHEMIA (INCREASED HAEMOGLOBIN):

- 1) People in higher altitudes (Physiological)
- 2) Smoking (Secondary Polycythemia)
- 3) Dehydration produces a falsely rise in hemoglobin due to increased haemoconcentration
- 4) Advanced lung disease (for example, emphysema)
- 5) Certain tumors
- 6) A disorder of the bone marrow known as polycythemia rubra vera,
- 7) Abuse of the drug erythropoetin (Epogen) by athletes for blood doping purposes (increasing the amount of oxygen available to the body by chemically raising the production of red blood cells).

NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)









A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

150000 - 450000

NAME : Mr. VIRENDER

AGE/ GENDER : 29 YRS/MALE **PATIENT ID** : 1792547

COLLECTED BY REG. NO./LAB NO. : 122503150024

REFERRED BY **REGISTRATION DATE** : 15/Mar/2025 04:51 PM BARCODE NO. : 12507523 **COLLECTION DATE** : 15/Mar/2025 04:58PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 15/Mar/2025 09:49PM

200000

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval Test Name**

PLATELET COUNT (P/C)

/cmm

PLATELET COUNT (PLT)

by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE &

MICROSCOPY

NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)





A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 pkrjainhealthcare@gmail.com

: 15/Mar/2025 10:22PM

NAME : Mr. VIRENDER

AGE/ GENDER : 29 YRS/MALE **PATIENT ID** : 1792547

COLLECTED BY REG. NO./LAB NO. : 122503150024

REFERRED BY **REGISTRATION DATE** : 15/Mar/2025 04:51 PM BARCODE NO. : 12507523 **COLLECTION DATE** : 15/Mar/2025 04:58PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

Value Unit **Biological Reference interval Test Name**

REPORTING DATE

GLYCOSYLATED HAEMOGLOBIN (HBA1C)

% GLYCOSYLATED HAEMOGLOBIN (HbA1c): 5.3 4.0 - 6.4

WHOLE BLOOD

by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)

mg/dL ESTIMATED AVERAGE PLASMA GLUCOSE 105.41 60.00 - 140.00 by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)

INTERPRETATION:

CLIENT CODE.

AS PER AMERICAN D	IABETES ASSOCIATION (ADA):	
REFERENCE GROUP	GLYCOSYLATED HEMOGLOGIB (HBAIC) in %	
Non diabetic Adults >= 18 years	<5.7	
At Risk (Prediabetes)	5.7 – 6.4	
Diagnosing Diabetes	>= 6.5	
•	Age > 19 Years	
	Goals of Therapy:	< 7.0
Therapeutic goals for glycemic control	Actions Suggested:	>8.0
	Age < 19 Years	
	Goal of therapy:	<7.5

COMMENTS:

- 1. Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients.
- 2. Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.
- 3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be 4.High

HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications

5. Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7. Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)







A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

NAME : Mr. VIRENDER

AGE/ GENDER : 29 YRS/MALE **PATIENT ID** : 1792547

COLLECTED BY REG. NO./LAB NO. : 122503150024

REFERRED BY **REGISTRATION DATE** : 15/Mar/2025 04:51 PM BARCODE NO. : 12507523 **COLLECTION DATE** : 15/Mar/2025 04:58PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 15/Mar/2025 10:22PM


CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval**

LIFOTRONIC Graph Report

Name :	Case:	Patient Type :	Test Date: 15/03/2025 22:17:30
Age:	Department:	Sample Type: Whole Blood EDTA	Sample ld: 12507523
Gender:			Total Area: 10807

Peak Name	Retention Time(s)	Absorbance	Area	Result (Area %)
HbA0	69	2145	9712	84.5
HbA1c	36	51	615	5.3
La1c	26	32	256	2.2
HbF	18	15	20	0.2
Hba1b	14	32	159	1.4
Hba1a	10	19	45	0.4





CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)



A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

NAME : Mr. VIRENDER

AGE/ GENDER : 29 YRS/MALE **PATIENT ID** : 1792547

COLLECTED BY : 122503150024 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 15/Mar/2025 04:51 PM BARCODE NO. : 12507523 **COLLECTION DATE** : 15/Mar/2025 04:58PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 15/Mar/2025 10:25PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval**

PROTHROMBIN TIME STUDIES (PT/INR)

PT TEST (PATIENT) by PHOTO OPTICAL CLOT DETECTION	12.1	SECS	11.5 - 14.5
PT (CONTROL) by PHOTO OPTICAL CLOT DETECTION	12	SECS	
ISI by PHOTO OPTICAL CLOT DETECTION	1.1		
INTERNATIONAL NORMALISED RATIO (INR) by PHOTO OPTICAL CLOT DETECTION	1.01		0.80 - 1.20
PT INDEX by PHOTO OPTICAL CLOT DETECTION	99.17	%	

INTERPRETATION:-

- 1.INR is the parameter of choice in monitoring adequacy of oral anti-coagulant therapy. Appropriate therapeutic range varies with the disease and treatment intensity.
- 2. Prolonged INR suggests potential bleeding disorder /bleeding complications
- 3. Results should be clinically correlated.
- 4. Test conducted on Citrated Plasma

RECOMMENDED THERAPEUTIC RANGE FOR ORAL ANTI-COAGULANT THERAPY (INR)			
INDICATION		INTERNATIONAL NORMALIZED RATIO (INR)	
Treatment of venous thrombosis			
Treatment of pulmonary embolism			
Prevention of systemic embolism in tissue heart valves			
Valvular heart disease	Low Intensity	2.0 - 3.0	
Acute myocardial infarction			
Atrial fibrillation			
Bileaflet mechanical valve in aortic position			
Recurrent embolism			
Mechanical heart valve	High Intensity	2.5 - 3.5	
Antiphospholipid antibodies ⁺			

COMMENTS:



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)





A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

: Mr. VIRENDER **NAME**

AGE/ GENDER : 29 YRS/MALE **PATIENT ID** : 1792547

COLLECTED BY REG. NO./LAB NO. : 122503150024

REFERRED BY **REGISTRATION DATE** : 15/Mar/2025 04:51 PM BARCODE NO. : 12507523 **COLLECTION DATE** : 15/Mar/2025 04:58PM

CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 15/Mar/2025 10:25PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval**

The prothrombin time (PT) and its derived measures of prothrombin ratio (PR) and international normalized ratio (INR) are measures of the efficacy of the extrinsic pathway of coagulation. PT test reflects the adequacy of factors I (fibrinogen), II (prothrombin), V, VII, and X. It is used in conjunction with the activated partial thromboplastin time (aPTT) which measures the intrinsic pathway.

The common causes of prolonged prothrombin time are:

1. Oral Anticoagulant therapy.

2.Liver disease. 3. Vit K. deficiency.

4. Disseminated intra vascular coagulation.

5. Factor 5, 7, 10 or Prothrombin dificiency



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)





A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

NAME : Mr. VIRENDER

AGE/ GENDER : 29 YRS/MALE **PATIENT ID** : 1792547

COLLECTED BY REG. NO./LAB NO. : 122503150024

REFERRED BY **REGISTRATION DATE** : 15/Mar/2025 04:51 PM BARCODE NO. : 12507523 **COLLECTION DATE** : 15/Mar/2025 04:58PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 15/Mar/2025 05:10PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval Test Name**

IMMUNOPATHOLOGY/SEROLOGY HEPATITIS C VIRUS (HCV) ANTIBODIES SCREENING

HEPATITIS C ANTIBODY (HCV) TOTAL

NON - REACTIVE

RESULT

by IMMUNOCHROMATOGRAPHY

INTERPRETATION:

1.Anti HCV total antibody assay identifies presence IgG antibodies in the serum. It is a useful screening test with a specificity of nearly 99%. 2.It becomes positive approximately 24 weeks after exposure. The test can not isolate an active ongoing HCV infection from an old infection that has been cleared. All positive results must be confirmed for active disease by an HCV PCR test.

FALSE NEGATIVE RESULTS SEEN IN:

1. Window period

2.Immunocompromised states.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)







A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 pkrjainhealthcare@gmail.com

NAME : Mr. VIRENDER

AGE/ GENDER : 29 YRS/MALE **PATIENT ID** : 1792547

COLLECTED BY REG. NO./LAB NO. : 122503150024

REFERRED BY **REGISTRATION DATE** : 15/Mar/2025 04:51 PM BARCODE NO. : 12507523 **COLLECTION DATE** : 15/Mar/2025 04:58PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 15/Mar/2025 05:10PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval**

ANTI HUMAN IMMUNODEFICIENCY VIRUS (HIV) ANTIBODIES HIV (1 & 2) SCREENING

HIV 1/2 AND P24 ANTIGEN RESULT

NON - REACTIVE

by IMMUNOCHROMATOGRAPHY

INTERPRETATION:-

- 1.AIDS is caused by at least 2 known types of HIV viruses, HIV-1 and HIV HIV-2.
- 2. This NACO approved immuno-chromatographic solid phase ELISA assay detects antibodies against both HIV-1 and HIV-2 viruses.
- 3.The test is used for routine serologic screening of patients at risk for HIV-1 or HIV-2 infection.
- 4.All screening ELISA assays for HIV antibody detection have high sensitivity but have low specificity.
- 5.At this laboratory, all positive samples are cross checked for positivity with two alternate assays prior to reporting.

- 1. Confirmatory testing by Western blot is recommended for patients who are reactive for HIV by this assay.
- 2.Antibodies against HIV-1 and HIV-2 are usually not detectable until 6 to 12 weeks following exposure (window period) and are almost always detectable by 12 months.
- 3. The test is not recommended for children born to HIV infected mothers till the child turns two years old (as HIV antibodies may be transmitted passively to the child trans-placentally).

FALSE NEGATIVE RESULT SEEN IN:

- 1. Window period
- 2. Severe immuno-suppression including advanced AIDS.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)







A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 pkrjainhealthcare@gmail.com

NAME : Mr. VIRENDER

AGE/ GENDER : 29 YRS/MALE **PATIENT ID** : 1792547

COLLECTED BY REG. NO./LAB NO. : 122503150024

REFERRED BY **REGISTRATION DATE** : 15/Mar/2025 04:51 PM BARCODE NO. : 12507523 **COLLECTION DATE** : 15/Mar/2025 04:58PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 15/Mar/2025 05:10PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval Test Name**

HEPATITIS B SURFACE ANTIGEN (HBsAg) SCREENING

HEPATITIS B SURFACE ANTIGEN (HBsAg)

NON - REACTIVE

by IMMUNOCHROMATOGRAPHY

INTERPRETATION:-

1.HBsAG is the first serological marker of HBV infection to appear in the blood (approximately 30-60 days after infection and prior to the onset of clinical disease). It is also the last viral protein to disappear from blood and usually disappears by three months after infection in self limiting acute Hepatitis B viral infection.

2.Persistence of HBsAg in blood for more than six months implies chronic infection. It is the most common marker used for diagnosis of an acute Hepatitis B infection but has very limited role in assessing patients suffering from chronic hepatitis.

FALSE NEGATIVE RESULT SEEN IN:

- 1. Window period.
- 2.Infection with HBsAg mutant strains
- 3. Hepatitis B Surface antigen (HBsAq) is the earliest indicator of HBV infection. Usually it appears in 27 41 days (as early as 14 days).
- 4.Appears 7 26 days before biochemical abnormalities. Peaks as ALT rises. Persists during the acute illness. Usually disappears 12-20 weeks after the onset of symptoms / laboratory abnormalities in 90% of cases.
- 5.Is the most reliable serologic marker of HBV infection. Persistence > 6 months defines carrier state. May also be found in chronic infection. Hepatitis B vaccination does not cause a positive HBsAg. Titers are not of clinical value.

NOTE:-

1.All reactive HBsAG Should be reconfirmed with neutralization test(HBsAg confirmatory test).

2.Anti - HAV IgM appears at the same time as symptoms in > 99% of cases, peaks within the first month, becomes nondetectable in 12 months (usually 6 months). Presence confirms diagnosis of recent acute infection.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)



A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 pkrjainhealthcare@gmail.com

: 15/Mar/2025 05:10PM

NAME : Mr. VIRENDER

AGE/ GENDER : 29 YRS/MALE **PATIENT ID** : 1792547

COLLECTED BY : 122503150024 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 15/Mar/2025 04:51 PM BARCODE NO. : 12507523 **COLLECTION DATE** : 15/Mar/2025 04:58PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

Value Unit **Biological Reference interval Test Name**

REPORTING DATE

VDRI.

VDRL NON - REACTIVE NON REACTIVE

by IMMUNOCHROMATOGRAPHY

INTERPRETATION:

CLIENT CODE.

1. Does not become positive until 7 - 10 days after appearance of chancre.

2. High titer (>1:16) - active disease.

- 3.Low titer (<1:8) biological falsepositive test in 90% cases or due to late or late latent syphillis.
- 4.Treatment of primary syphillis causes progressive decline tonegative VDRL within 2 years.
- 5. Rising titer (4X) indicates relapse, reinfection, or treatment failure and need for retreatment.
- 6. May benonreactive in early primary, late latent, and late syphillis (approx. 25% ofcases).

7. Reactive and weakly reactive tests should always be confirmed with FTA-ABS (fluorescent treponemal antibody absorption test).

SHORTTERM FALSE POSITIVE TEST RESULTS (<6 MONTHS DURATION) MAY OCCURIN:

- 1. Acute viral illnesses (e.g., hepatitis, measles, infectious mononucleosis)
- 2.M. pneumoniae; Chlamydia; Malaria infection.
- 3. Some immunizations
- 4. Pregnancy (rare)

LONGTERM FALSE POSITIVE TEST RESULTS (>6 MONTHS DURATION) MAY OCCUR IN:

- 1. Serious underlying disease e.g., collagen vascular diseases, leprosy, malignancy.
- 2.Intravenous drug users.
- 3. Rheumatoid arthritis, thyroiditis, AIDS, Sjogren's syndrome.
- 4.<10 % of patients older thanage 70 years.
- 5. Patients taking some anti-hypertensive drugs.

*** End Of Report ***



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)